Date: 2016-06-09
Type of information: Production agreement
Compound: Lenti-D™ and LentiGlobin™ drug products
Company: Bluebird bio (USA - MA) Lonza (Switzerland)
Therapeutic area: Technology - Services
Type agreement: manufacturing production
Action mechanism: gene therapy.
Disease:
Details: * On June 9, 2016, Lonza Houston and bluebird bio have entered into a strategic manufacturing agreement providing for the future commercial production of bluebird bio’s Lenti-D™ and LentiGlobin™ drug products. This agreement follows a successful multi-year clinical manufacturing relationship and provides bluebird bio with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. This facility is currently under construction, for the clinical and commercial supply of viral vectors and virally-modified cell therapy products.
Under this multi-year agreement, Lonza will complete the suite design, construction and validation along with process validation prior to anticipated commercial launch.
Financial terms:
Latest news:
